tbuckley/cabot-search huggingface dataset:
Abstract 4915: Estrogen receptor β is expressed within breast cancer cells with stem cell like capacity and confers endocrine sensitivity.
Authors: Ran Ma, Karthik Muralidharan Govindasamy, Gustaf Rosin, John Gustafsson, Anne Katchy, Linda Lindström, Camilla Hilliges, Lisa Viberg, Lennart Blomqvist, Jan Frisell, Cecilia Williams, Irma Fredriksson, Jonas Bergh, Johan Hartman
Journal: Cancer Research (2013)

Abstract Breast cancer stem-cells (BCSCs) are tumor-initiating cells expressing classical embryonal genes such as NANOG, SOX2 and NOTCH1, with a capacity to differentiate and form the heterogenous tumor mass in breast cancer. BCSCs are defined by their potential to grow as mammospheres in vitro together with their distinct cell-surface antigenic profile CD44+/CD24-/EpCAMlow as well as ALDH1-expression. It has been suggested that BCSCs are responsible for therapeutical resistance and metastasis. About 70-80% of diagnosed breast cancers express ERα, which is demonstrated to have a central role in breast cancer progression and considered as a marker for endocrine sensitivity. However, in our research, BCSCs are confirmed to be ERα negative and supposed to be responding to estrogens only through paracrine signaling via stromal cells. We show that BCSCs purified from fresh surgically resected breast cancers express the second estrogen receptor; ERβ. It is also present in normal mammary stem cells (MSCs) isolated from breast reduction specimens. Surprisingly, stimulation of ERβ with a specific agonist expands the population of BCSCs but not MSCs . Knockdown of ERβ causes reduction in the number of mammospheres significantly along with decreased ALDH1 expression. We also find that treatment with tamoxifen is not sufficient to inhibit BCSCs proliferation although a specific ERβ antagonist reduces tumor growth in xenograft experiments as well as inhibits proliferation of primary cancer stem cells. In conclusion, we suggest endogenous ERβ is proliferative in cancer stem cells in vivo and in vitro, thus can be targeted by specific ligands, in turn opening up for a new direction in endocrine stem-cell specific therapy for breast cancer. Citation Format: Ran Ma, Karthik Muralidharan Govindasamy, Gustaf Rosin, John Gustafsson, Anne Katchy, Linda Lindström, Camilla Hilliges, Lisa Viberg, Lennart Blomqvist, Jan Frisell, Cecilia Williams, Irma Fredriksson, Jonas Bergh, Johan Hartman. Estrogen receptor β is expressed within breast cancer cells with stem cell like capacity and confers endocrine sensitivity. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 4915. doi:10.1158/1538-7445.AM2013-4915
Structure-based optimization of GRP78-binding peptides that enhances efficacy in cancer imaging and therapy
Authors: Sheng-Hung Wang, Andy Chi-Lung Lee, I-Ju Chen, Nai-Chuan Chang, Han-Chung Wu, Hui-Ming Yu, Ya-Jen Chang, Te-Wei Lee, Jyh-Cherng Yu, Alice L. Yu, John Yu
Journal: Biomaterials (2016)
Abstract 3735: Increased efficacy with use of combination therapy of API 31510 and gemcitabine in the treatment of pancreatic cancer
Authors: Niven R. Narain, Rangaprasad Sarangarajan, Rakib Ouro-Djobo, Justin J. Bourdelais, Eric Grund, Vivek Vishnudas, Lucia M. Mauro, Assuan Lens, Adel Yunis, Shuili Agarwal, Paul Y. Song, John P. McCook, Joaquin J. Jimenez
Journal: Cancer Research (2012)

Abstract Pancreatic Carcinoma is one of the deadliest types of cancers and certainly one that is most clinically difficult to manage given that most diagnoses occur in late-stage disease. Gemcitabine is among the few FDA approved drugs used alone and in combination with other antineoplastic agents for pancreatic cancer. API 31510, a novel intravenous formulation of Ubidecarone, induced superior cell death kinetics in pancreatic carcinoma cell line, MiaPaca alone or in combination with gemcitabine. In addition, the study employed an in vivo model of pancreatic cancer to assess the translation of the cell-based data of combination gemcitabine and API 31510. Animals were randomized into 4 groups of 30 rats each; group 1 received no treatment, group 2 received gemcitabine (150 mg/kg weekly for 3 weeks with one week rest), group 3 were injected with API 31510 (50 mg/kg daily), and group 4 received a combination of daily API 31510 (50kg/mg) and gemcitabine at the aforementioned regimen. The untreated group exhibited steep death rates, whereas in API 31510, gemcitabine alone and the combination of API 31510 resulted in prolongation of life. API 31510 alone had significantly greater impact than gemcitabine alone. Animals treated with gemcitabine + API 31510 exhibited prolonged survival and elicited long-term remission that was statistically significant compared to other groups. In addition, palpable tumors were decreased in the groups treated with API 31510, and to a greater degree, in those treated with gemcitabine in combination with API 31510. It is noteworthy that tumor histology demonstrated a hallmark disruption in tumor vasculature with use if API 31510. Taken together, these findings suggest that API 31510 offers a new approach to treatment and management of pancreatic cancer alone and combination with established chemotherapy regimens that include gemcitabine. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 3735. doi:1538-7445.AM2012-3735
SAT0020 Rheumatoid Arthritis (RA) Patients Have Similar Excellent Outcomes After Total Knee Replacement Compared with Osteoarthritis (OA) Patients
Authors: S. M. Goodman, B. Johnson, W.-T. Huang, M. P. Figgie, M. Alexiades, L. A. Mandl
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Rheumatoid arthritis (RA) patients have worse reported outcomes after total knee replacement (TKR) as compared with osteoarthritis (OA) patients. It is unknown if this persists in a contemporary cohort of RA patients with high DMARD and biologic use. <h3>Objectives</h3> To compare baseline and 2 year outcomes of primary and revision TKR (RTKR) in patients with RA versus OA. <h3>Methods</h3> All TKR and RTKR enrolled in a single institution registry between 5/1/2007 and 7/1/2010 with pre-operative data and who were alive at two years were eligible for this analysis. Patients with two eligible procedures only contributed data from the second. RA cases were identified by self report or ICD-9 code and validated by chart review. Patients with ICD-9 codes for other systemic rheumatic disease or fractures were excluded. Satisfaction at 2 years was measured on a 5-point Likert scale. Differences between groups were compared using unpaired Student’s t test, Chi-Square or Fisher’s exact test as appropriate. <h3>Results</h3> 5,384 primary TKR and 374 RTKR were eligible for this study with 178 RA TKR and 32 RA RTKR. 94% had 2-year follow-up. (Table 1) More TKR RA cases were female with lower BMI and more comorbidities. 81% of RA TKR were on DMARD therapy, 44% on biologics; RTKR 87% and 50% respectively. RA TKR had significantly worse pain and function pre-operatively but no difference at 2 years. RA and OA had similar clinically meaningful improvements in pain and function, (WOMAC change &gt;10) and similar numbers of patients with poor 2-year outcomes (WOMAC pain or function≤ 60). Satisfaction was high for both groups. For RTKR, OA and RA patients had similar pain and function pre-operatively, but RA had significantly less pain and better function at 2 years. OA RTKR were much less satisfied at 2 years. <h3>Conclusions</h3> Although contemporary RA patients undergoing TKR have worse pre-operative pain and function compared with OA patients, they have comparable 2 year outcomes. By contrast, RTKR RA patients have less pain and better function at 2 years than OA RTKR- differences which were clinically meaningful. These data demonstrate excellent results in contemporary RA TKR and RTKA patients. <h3>Disclosure of Interest</h3> None Declared
I-123 Uptake in Nonfunctional Struma Ovarii
Authors: IKUO JOJA, TORU ASAKAWA, AKIHITO MITSUMORI, TOMIO NAKAGAWA, SHIRO AKAKI, MICHINORI YAMAMOTO, YOSHIHIRO TAKEDA, MASAAKI ANDO, YOSHIO HIRAKI
Journal: Clinical Nuclear Medicine (1998)

A case of nonfunctional struma ovarii preoperatively diagnosed by scintigraphy of the pelvis using I-123 Nal is reported. US, CT, and MRI revealed a multilobulated mass composed of cystic and solid components. CT showed cystic components with slightly high density and MRI showed various signal intensities on T1- and T2-weighted images. I-123-scintigraphy of the pelvis showed uptake in the pelvic mass. Microscopic examination revealed the histologic appearance of thyroid tissue accompanied by follicular adenoma. I-123 scintigraphy of the pelvis was useful for reaching the correct preoperative diagnosis in this patient with nonfunctional struma ovarii.
Infection of a Left Ventricular Aneurysm and Massive Splenomegaly Demonstrated by In-111-Labeled Leukocyte Scintigraphy
Authors: DAVID S. ROSE, BRAHM SHAPIRO
Journal: Clinical Nuclear Medicine (1998)

When septicemia has failed to resolve after appropriate antibiotic therapy, labeled leukocyte scintigraphy is often valuable to locate focal sites of infection. In this case, probable infection of a left ventricular aneurysm, the sequela of an old myocardial infarction, was demonstrated. Massive splenomegaly due to portal vein stenosis after prior orthotopic liver transplantation also was depicted. In previously reported cases of infected left ventricular aneurysms, there usually has been prior myocardial infarction. As in this case, associated mural thrombus and false aneurysms have been reported. Demonstration by labeled leukocyte scintigraphy has not been previously reported.
Endoscopic ultrasound-guided tissue acquisition: does the needle make the difference?
Authors: Julio Iglesias-Garcia, J. Domínguez-Muñoz
Journal: Endoscopy (2016)

Endoscopic ultrasound (EUS)-guided tissue acquisition is a widespread technique used to obtain tissue samples for histological diagnosis in patients suffering from intraintestinal and extraintestinal lesions, such as pancreatic tumors, lymph node enlargement, or subepithelial masses [1] [2]. However, the diagnostic capability of EUS-guided fine-needle aspiration (FNA) is limited if on-site cytopathological evaluation, which is associated with greater sample adequacy and diagnostic accuracy, is not available [3]. Rapid on-site cytological evaluation is very demanding, requiring a high level of expertise from pathologists who often have very scant tissue material to work with. Nonetheless, in the published literature, the diagnostic accuracy of EUS-FNA has reached sensitivity rates of over 90 % [2]. However, these data relate to “perfect conditions” – a very experienced endonosographer working with an expert pathologist in the setting of rapid on-site evaluation. In not-so-perfect conditions, the diagnostic sensitivity can decrease to 70 % – 75 % [4].
Deficiency of Glutathione Peroxidase Associated with High Levels of Reduced Glutathione in Glanzmann's Thrombasthenia
Authors: Simon Karpatkin, Harvey J. Weiss
Journal: New England Journal of Medicine (1972)

Abstract Six patients with documented defects in platelet function were screened for possible abnormalities in platelet energy metabolism and reductive capacity. Abnormalities found in the reductiv...
IRON-CONTAINING AGENTS - FE-59 FATE.
Authors: Barry L. Engelstad, David C. Price, Thornton Sargent, John P. Huberty, Kurt A. Muetterties, David L. White
Journal: Clinical Nuclear Medicine (1988)

Engelstad, Barry L.; Price, David C.; Sargent, Thornton III; Huberty, John P.; Muetterties, Kurt A.; White, David L. Author Information
Differential abilities of the Raf family of protein kinases to abrogate cytokine dependency and prevent apoptosis in murine hematopoietic cells by a MEK1-dependent mechanism
Authors: PE Hoyle, PW Moye, LS Steelman, WL Blalock, RA Franklin, M Pearce, H Cherwinski, E Bosch, M McMahon, JA McCubrey
Journal: Leukemia (2000)
Case 34-2012
Authors: Birhanu Sendek Getahun, Melisachew M. Yeshi, Drucilla J. Roberts
Journal: New England Journal of Medicine (2012)

A 27-year-old woman was admitted to a hospital in Ethiopia because of severe abdominal pain during labor, with cessation of contractions. She had been in labor at home, pushing for 24 hours. On arrival at the hospital 3 hours later, she was in shock. A procedure was performed.
Incidence Rates of Lymphomas and Soft-Tissue Sarcomas and Environmental Measurements of Phenoxy Herbicides
Authors: P Vineis, F Faggiano, M Tedeschi, G Ciccone
Journal: JNCI Journal of the National Cancer Institute (1991)

Journal Article Incidence Rates of Lymphomas and Soft-Tissue Sarcomas and Environmental Measurements of Phenoxy Herbicides Get access Paolo Vineis, Paolo Vineis Search for other works by this author on: Oxford Academic PubMed Google Scholar Fabrizio Faggiano, Fabrizio Faggiano Search for other works by this author on: Oxford Academic PubMed Google Scholar Martine Tedeschi, Martine Tedeschi Search for other works by this author on: Oxford Academic PubMed Google Scholar Giovannino Ciccone Giovannino Ciccone Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 83, Issue 5, 6 March 1991, Pages 362–364, https://doi.org/10.1093/jnci/83.5.362 Published: 06 March 1991 Article history Received: 21 September 1990 Revision received: 29 November 1990 Accepted: 11 December 1990 Published: 06 March 1991
Drugs and Thyroid Function
Authors: Martin I. Surks, Rubens Sievert
Journal: New England Journal of Medicine (1995)

Testing of thyroid function is common in clinical practice. Many patients who are tested, including those who have or are receiving treatment for thyroid disease, take medications that may affect thyroid function. Therefore, the possible effect of these drugs both on the results of thyroid-function tests and on the effectiveness of treatment must always be considered in decisions regarding patient care.The pathways of thyroid hormone synthesis, secretion, transport in the circulation, and metabolism offer numerous targets for drug interaction (Figure 1 and Figure 2). Normal thyroid secretion depends on thyrotropin (TSH). Secretion of TSH is, in turn, inhibited by thyroid hormones . . .
P630 AUTOPHAGY REGULATES HEPATOCYTES DIFFERENTIATION DURING EPITHELIAL TO MESENCHYMAL (EMT) AND MESENCHYMAL TO EPITHELIAL TRANSITION (MET) BY PROMOTING SNAIL DEGRADATION
Authors: G. Grassi, G. Di Caprio, L. Santangelo, M. Komatsu, G.M. Fimia, M. Piacentini, M. Tripodi, T. Alonzi
Journal: Journal of Hepatology (2014)
THU0392 Anti-TNFα Therapy in Refractory Sarcoid Uveitis: Multicenter Study of 16 Cases
Authors: M. Santos-Gόmez, V. Calvo-Río, M. Mesquida, R. Blanco-Alonso, J.M. Herreras, M. Cordero-Coma, N. Ortego, Ά. M. García-Aparicio, J. Sánchez-Bursόn, D. Peiteado-Lόpez, A. Adan, L.F. Linares Ferrando, A. Follonosa, F. Ortiz-Sanjuán, T. Pina, M.C. González-Vela, J. Loricera, M.Ά. González-Gay
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Objectives</h3> To assess the efficacy of anti-TNFα drugs in Sarcoid Uveitis (SU) refractory to conventional synthetic immunosuppressive drugs (CSISDs). <h3>Methods</h3> Multicenter study (12 hospitals) of refractory SU to oral corticosteroids and at least one CSISD. Ocular inflammation was evaluated according to "SUN-2005", and macular thickness by OCT. Results are expressed as mean ± SD (normal distribution), or as median [25th-75th interquartile range (IQR)] (not normally distributed) and Comparison by Wilcoxon test. <h3>Results</h3> We studied 16 patients/27 eyes (7men/9women) with a mean age of 38.4±17.2 years (range 13-76). They showed: elevated Angiotensin-Converting Enzyme (56.2%), bilateral hiliar lymphadenopathy (56.2%), lung parenchymal involvement (43.7%), and involvement of other organs (56.2%). A biopsy confirmed sarcoidosis in the 31.2% of cases. The most frequent pattern of uveitis was bilateral chronic remitting panuveitis and the most frequent ocular inflammatory findings were mutton-fat keratic precipitates and snow balls in vitreous. Besides oral corticosteroids and before anti-TNFα, patients had received i.v. methylprednisolone (n=1), methotrexate (n=12), cyclosporine A (n=5), or azathioprine (n=3). The first anti-TNFα was: adalimumab (n=9; 56.3%) (40 mg/sc/2 weeks) and infliximab (n=7; 43.7%) (5 mg/kg/i.v./every 4-8 weeks), and was used in combination (n=13) with MTX (n=10), AZA (n=2) and mycophenolate mofetil (n=1). Infliximab was successfully switched to golimumab (n=2) due to intolerance. The mean duration of anti-TNFα was 27.7±16.8 months. The results with anti-TNFα after 2 years were: Visual acuity: from a mean of 0.6±0.3 to 0.8±0.2 (p=0.03); Tyndall: from a median of 1 [IQR: 0-3] to 0 [IQR: 0-2] (p=0.017) and vitritis: from a median of 0 [IQR: 0-3] to 0 [IQR: 0-1] (p=0.03). Six patients (7 eyes) with cystoid macular edema (CME) (OCT&gt;300μ) at baseline, improved from 372±58.3 to 241±1.4 microns at 2 years (p=0.17). <h3>Conclusions</h3> Anti-TNF therapy seems effective in SU refractory to CSISDs. <h3>Acknowledgements</h3> This study was supported by a grant from "Fondo de Investigaciones Sanitarias"PI12/00193 (Spain). This work was also partially supported by RETICS Programs, RD08/0075 (RIER) and RD12/0009/0013 from"Instituto de Salud Carlos III" (ISCIII) (Spain). <h3>Disclosure of Interest</h3> : None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.3829
FRI0416 Effect of treatment with tumor necrosis factor inhibitors (TNFI) on bone mineral density (BMD) in patients with ankylosing spondylitis (AS) : a systematic review.
Authors: N. Nigil Haroon, N. AlGhanim, R. D. Inman, A. M. Cheung
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Osteoporosis (OP) and related fractures occur in patients with AS. No guidelines exist for treating OP in patients with AS.TNFI are increasingly used for treating AS. If TNFIs are proven to prevent or revert bone loss, use of other treatments of OP can be avoided. <h3>Objectives</h3> To study the effect of TNF inhibitors on spine and hip BMD in patients with AS. <h3>Methods</h3> Two authors searched MEDLINE, EMBASE &amp; Cochrane databases (inception to Dec 31, 2012), reviewed abstracts, read selected articles in full&amp; extracted data. Discrepancies were resolved by a 3rd author. Studies with minimum 6 months follow up &amp; at least 70% of subjects satisfying Modified New York for AS criteria were included. Spine &amp; hip BMD at 1 &amp; 2 years were the primary outcomes. We excluded case reports &amp; studies on children &amp; adolescents. The quality of studies were assessed by Newcastle–Ottawa Quality Assessment Scale. <h3>Results</h3> The 5207 titles retrieved were narrowed down to 7 studies (1 RCT, 3 case control and case studies each) that measured outcomes at 6 months (3 studies, 91% Infliximab (I), 5% Etanercept (E), and 14% Adalimumab (A)),1 year (5 studies,42% I, 31% E and 27% A), 2 years (4 studies,71%I,15% E &amp;14% A) &amp; 3 years(1 study). 76-92% were males. Only 2.6% (n=12) got bisphosphonates. Little data was available on calcium intake, vitamin D intake &amp; fracture incidence. Spine BMD increased with TNFI treatment in all studies. The effect was significant compared to controls (4 studies). The effect was noted as early as 6 months &amp; lasted up to 3 years with continued therapy, except in 1 study (n=19, where the change was similar to those on NSAIDs/bisphosphonates(Table 1). Change in spine BMD at 2 years ranged from 5.8-11%. Hip BMD remained stable/ improved by 1.9-2.3% and 1.8-3.5% at 1 &amp; 2 years, respectively. BMD gain correlated to ESR reduction &amp; baseline mSASSS. On multivariate regression analyses, baseline BMD predicted BMD gain. Syndesmophytes did not influence the response of BMD to TNFIs. <h3>Image/graph</h3> <h3>Conclusions</h3> Treatment with TNF inhibitors improve spine and hip BMD as early as 6 months. On continued treatment, the improvement lasts up to 3 years. <h3>References</h3> <h3>Disclosure of Interest</h3> N. Nigil Haroon Grant/research support from: AMGEN Canada, N. AlGhanim: None Declared, R. Inman Consultant for: AMGEN, PFIZER and VYETH, A. Cheung Grant/research support from: AMGEN and PFIZER, Consultant for: AMGEN
Comparison of Tc-99m MIBI and Tl-201/Tc-99m Pertechnetate for Diagnosis of Primary Hyperparathyroidism
Authors: John D. Rauth, Roy B. Sessions, Susan C. Shupe, Harvey A. Ziessman
Journal: Clinical Nuclear Medicine (1996)

The purpose of this study was to directly compare the efficacy of Tc-99m MIBI with TI-201/Tc-99m pertechnetate scintigraphy for localizing parathyroid adenomas in patients with primary hyperparathyroidism. Of 21 patients suspected of having primary hyperparathyroidism who had undergone both studies, 14 had subsequent surgery and pathologic correlation. Based on the surgical and pathologic results, Tc-99m MIBI yielded 13 true-positive and 1 false-negative result. Thallium-201/ Tc-99m pertechnetate imaging yielded eight true-positive, four false-negative, and two nondiagnostic studies because of lack of Tc-99m pertechnetate uptake from thyroid hormone suppression. In conclusion, Tc-99m MIBI scintigraphy is an accurate method for localizing parathyroid adenomas in patients with primary hyperparathyroidism and the results suggest that it is superior to using TI-201/Tc-99m pertechnetate.
The 12-month analysis from Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT): A phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinoma
Authors: Reinhard Dummer, Alexander Guminski, Ralf Gutzmer, Luc Dirix, Karl D. Lewis, Patrick Combemale, Robert M. Herd, Martin Kaatz, Carmen Loquai, Alexander J. Stratigos, Hans-Joachim Schulze, Ruth Plummer, Sven Gogov, Celine Pallaud, Tingting Yi, Manisha Mone, Anne Lynn S. Chang, Frank Cornélis, Ragini Kudchadkar, Uwe Trefzer, John T. Lear, Dalila Sellami, Michael R. Migden
Journal: Journal of the American Academy of Dermatology (2016)

The hedgehog pathway inhibitor sonidegib demonstrated meaningful tumor shrinkage in more than 90% of patients with locally advanced basal cell carcinoma (BCC) or metastatic BCC in the BCC Outcomes with LDE225 Treatment study.This report provides long-term follow-up data collected up to 12 months after the last patient was randomized.In this multicenter, randomized, double-blind phase II study, patients were randomized 1:2 to sonidegib 200 or 800 mg. The primary end point was objective response rate assessed by central review.Objective response rates in the 200- and 800-mg arms were 57.6% and 43.8% in locally advanced BCC and 7.7% and 17.4% in metastatic BCC, respectively. Among the 94 patients with locally advanced BCC who responded, only 18 progressed or died and more than 50% had responses lasting longer than 6 months. In addition, 4 of 5 responders with metastatic BCC maintained an objective response. Grade 3/4 adverse events and those leading to discontinuation were less frequent with sonidegib 200 versus 800 mg (38.0% vs 59.3%; 27.8% vs 37.3%, respectively).No placebo or comparator arms were used because sonidegib demonstrated efficacy in advanced BCC in a phase I study, and the hedgehog pathway inhibitor vismodegib was not yet approved.With longer follow-up, sonidegib demonstrated sustained tumor responses in patients with advanced BCC.